Pituitary Incidentalomas

How to Cite This Chapter: Khan T. Pituitary Incidentalomas. McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. https://empendium.com/mcmtextbook/chapter/B31.II.8.8. Accessed October 27, 2021.
Last Updated: December 28, 2020
Last Reviewed: June 11, 2021
Chapter Information

Definition, Etiology, PathogenesisTop

A pituitary incidentaloma (PI) is generally defined as a pituitary lesion identified on brain imaging performed for an unrelated reason. The prevalence of pituitary adenomas varies widely; autopsy studies report a prevalence between 3% and 27%, while imaging studies report a prevalence of ~10%. By convention masses <1 cm are called microadenomas, while those >1 cm are called macroadenomas.

The true pathologic etiology of most PIs remains unknown, since most PIs do not require surgical intervention. Of those that require surgery, the majority (>90%) are pituitary adenomas, while the rest include etiologies such as Rathke cleft cysts, meningiomas, craniopharyngiomas, germinomas, and metastases (Table 6.3-1). The pathogenesis of PIs is believed to be a multistep process, through genetic and epigenetic mechanisms conferring growth advantage to a particular type of cells, resulting in their increase through clonal expansion.

Clinical FeaturesTop

PIs can cause symptoms through mass effect or by affecting hormone production. Roughly half (55%) of PIs are nonfunctioning in that they do not produce excessive pituitary hormones but can still cause symptoms due to secondary hormone deficiencies or local compressive symptoms. Adenomas that secrete excessive pituitary hormones can cause symptoms due to excessive secretion of a particular hormone or hormones in addition to compressive effects and secondary hormone deficiencies (Table 6.3-2). While prolactinomas and lesions leading to Cushing syndrome and acromegaly are seen more frequently, tumors secreting functionally active thyroid-stimulating hormone (TSH), luteinizing hormone (LH), or follicle-stimulating hormone (FSH) are exceedingly rare.

Local compressive symptoms may include periorbital headaches, visual field deficits due to compression of the optic chiasm, or less commonly ophthalmoplegia due to involvement of the cavernous sinus affecting cranial nerves III, IV, and VI.

DIAGNOSISTop

Clinical Assessment

All patients presenting with PIs should undergo clinical assessment for an excess or deficiency of anterior and posterior pituitary hormones as well as for symptoms due to mass effects. These assessments could help in determining the need for biochemical, radiographic, or visual field evaluation, as delineated below.

Diagnostic Tests

1. Biochemical testing for an excess or a deficiency of pituitary hormones should be carried out in patients presenting with PIs based on lesion size or presence of symptoms and signs. Pituitary hormone deficiencies are rare in microadenomas, suggesting the need for testing for hormonal deficiencies only in patients presenting with symptoms. However, testing for hormone deficiency should be done in all patients presenting with macroadenomas. Biochemical tests for hormonal oversecretion and undersecretion: Table 6.3-3.

In addition, testing for primary hypothyroidism (TSH) should also be done to exclude thyrotroph hyperplasia masquerading as a macroadenoma and responsive to medical therapy with levothyroxine, which does not require surgical treatment. It can present with hyperprolactinemia from stimulation of prolactin by thyrotropin-releasing hormone (TRH) in response to hypothyroidism. Prolactin should also be checked in all patients with PIs to determine if the lesion is a prolactinoma, which is usually medically treated. 

2. Formal visual field testing should be considered in patients in whom the PI is close to, or abuts, the optic nerves or chiasm on magnetic resonance imaging (MRI).

3. Imaging: A dedicated MRI of the sella should be performed at baseline in patients diagnosed with a PI using computed tomography (CT).

TREATMENTTop

Indications for Surgery

Patients with PIs who have evidence of hormonal hypersecretion (except for a prolactinoma, which is usually medically treated) should have surgery at the time of initial diagnosis, if possible. In addition, patients with visual field deficits, neurologic deficits due to compressive effects, visual disturbances due to pituitary apoplexy, or lesions abutting the optic nerves or chiasm should also be referred for surgery.

FOLLOW-UPTop

Follow-up for patients who do not undergo surgery or do not have pituitary hormone hypersecretion at initial diagnosis:

1) In patients with a microadenoma or macroadenoma, clinical assessment of pituitary deficiency should be undertaken 12 or 6 months after initial testing, respectively, and yearly thereafter.

2) Biochemical assessment for hypopituitarism should be carried out if there is a change in symptoms or increase in the size of the tumor.

3) MRI should be performed at 6 months in those with a macroadenoma and at 12 months in those with a microadenoma. If the lesion is stable, this interval can be changed to every year for those with a macroadenoma and every 1 to 2 years for those with a microadenoma in the 3 years post diagnosis, and the interval can be increased thereafter if the lesion remains stable until 5 years for a microadenoma and up to 10 years for a macroadenoma.

4) Visual field testing should be undertaken in patients whose PIs enlarge to abut or compress the optic nerves or chiasm on repeat imaging.

TableSTop

Table 6.3-1. Characterization of pituitary adenomas

Type of adenoma

Percentage

Nonfunctioning adenomas

55%

Rathke cleft cysts

14%

Prolactinomas

11%

Other pituitary cysts

5%

Somatotropinomas (GH secreting)

5%

Craniopharyngiomas

5%

Corticotropinomas (ACTH secreting)

2%

Meningiomas

2%

Arachnoid cysts

0.5%

Other lesions

0.5%

ACTH, adrenocorticotropic hormone; GH, growth hormone.

Table 6.3-2. Functioning pituitary adenomas

Type of adenoma

Hormone secreted

Prolactinoma

PRL

Corticotropinoma

ACTH

Somatotropinoma

GH

Thyrotropinoma

TSH (exceedingly rare)

Gonadotropinoma

FSH, LH (rarely functional)

ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; GH, growth hormone; LH, luteinizing hormone; PRL, prolactin; TSH, thyroid-stimulating hormone.

Table 6.3-3. Tests for pituitary hormone excess or deficiency

Pituitary hormone overproduction (usually if clinically suspected)

Test of choice

Prolactinoma

Serum prolactin measurement (in all)

Cushing syndrome

1-mg dexamethasone suppression test or late-night salivary cortisol test, or 24-h urinary free cortisol test

Acromegaly

Serum IGF-1 level

Thyrotropinoma

FT4, FT3, TSH

Pituitary hormone deficiency

Test of choice

Adrenal insufficiency

Early morning serum cortisol with ACTH measurement +/- ACTH stimulation test

Hypothyroidism

Serum TSH and FT4 measurement (FT4 measurement is the best test for central hypothyroidism)

Hypogonadism

Men: Early morning testosterone measurement with LH measurement

Women: Presence of menstrual periods in premenopausal women. In case of oligomenorrhea or amenorrhea: estradiol and FSH measurement

Central diabetes insipidus

Serum sodium measurement, serum and urine osmolality, water deprivation test if needed (in masses >1 cm and if symptoms are present)

ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; FT3, free triiodothyronine; FT4, free thyroxine; IGF-1, insulin-like growth factor 1; TSH, thyroid-stimulating hormone.

We would love to hear from you

  • Do you have any comments?
  • Have you found a mistake?
  • Would you like to suggest a feature?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.